Intra-cellular Therapies v. Sandoz: CAPLYTA® Lumateperone Patents Consolidated
Intra-cellular Therapies filed suit against Sandoz in the District of New Jersey asserting three patents covering CAPLYTA® lumateperone capsules against Sandoz’s proposed generic. Within 70 days, the case was consolidated into a lead multi-defendant action, suggesting parallel ANDA challenges from multiple generic filers.
Three-patent ANDA battle over CAPLYTA® funnelled into consolidated NJ docket
On 1 November 2024, Intra-cellular Therapies, Inc. filed a patent infringement action against Sandoz, Inc. in the U.S. District Court for the District of New Jersey (Case No. 3:24-cv-10239). The complaint asserted three recently issued U.S. patents — US12128043B2, US12122792B2, and US12090155B2 — covering formulations and methods of use related to lumateperone, marketed as CAPLYTA® in 10.5 mg, 21 mg, and 42 mg capsule strengths. Sandoz’s action is consistent with an ANDA filing seeking FDA approval to market a generic version of CAPLYTA® prior to patent expiry.
The case closed on 10 January 2025, just 70 days after filing, via consolidation into the lead action Civil Action No. 3:24-cv-04264. Under the consolidation order, all counsel admitted pro hac vice in any of the consolidated actions are deemed admitted in the lead case. This procedural step does not represent a merits ruling; rather, it streamlines pretrial management and signals that multiple generic manufacturers have filed ANDA challenges against CAPLYTA®, prompting the court to manage them under a single coordinated docket.
The swift consolidation within 70 days is consistent with standard Hatch-Waxman practice in New Jersey, where courts routinely consolidate parallel ANDA cases early to avoid duplicative discovery and claim construction. The public record does not disclose how many other defendants are named in the lead action, nor the specific grounds of invalidity or non-infringement raised by Sandoz. The substantive litigation — claim construction, validity, and infringement questions for all three patents — continues under the consolidated docket.
Filing to Case Consolidated in 70 days
70-day duration before consolidation — faster than median ANDA case resolution
Consolidation into lead action: what this procedural step means
Consolidation is not dismissal — litigation continues
Case consolidation under Fed. R. Civ. P. 42(a) merges related actions sharing common questions of law or fact into a single coordinated proceeding. This case was folded into lead action No. 3:24-cv-04264. No claims have been adjudicated, dismissed, or settled. All substantive patent disputes — validity, infringement, and claim scope — carry forward and will be resolved in the lead docket.
Procedural — no merits rulingIntra-cellular retains all three asserted patents
Consolidation does not prejudice Intra-cellular Therapies’ infringement claims. The company’s three lumateperone patents remain in suit, and the 30-month stay of FDA approval triggered by the Hatch-Waxman framework continues to run. Prosecuting claims in a consolidated action can also be strategically advantageous, allowing plaintiff to establish consistent infringement and validity positions across all generic challengers simultaneously.
Patents remain assertedSandoz faces coordinated multi-defendant proceeding
Sandoz’s case is now managed alongside other ANDA filers under a single docket. Consolidated proceedings typically accelerate claim construction schedules and can limit a single defendant’s ability to pursue independent litigation strategies. Sandoz will need to coordinate — or differentiate — its invalidity and non-infringement positions relative to co-defendants. The public record does not yet reveal which other generic manufacturers are consolidated in the lead action.
Litigation continues in lead docketMultiple ANDA filers signal high generic market interest in CAPLYTA®
The need to consolidate parallel actions suggests at least two generic manufacturers have filed ANDA challenges against CAPLYTA®, a product with significant commercial value in the CNS/psychiatry space. The outcome of the consolidated proceeding will determine when — if ever — a generic lumateperone product can enter the U.S. market. Companies monitoring CAPLYTA® competitive dynamics should track the lead docket No. 3:24-cv-04264 for claim construction orders and trial scheduling.
Generic entry timing at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Intra-cellular Therapies, Inc. | Company | CNS-focused biopharmaceutical company — holder of US12128043B2, US12122792B2, and US12090155B2Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Sandoz, Inc. — generic pharmaceutical manufacturer seeking ANDA approval for lumateperone capsulesSearch in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren Ruth Malakoff | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order’s operative language — admitting all pro hac vice counsel across consolidated actions into the lead case — is a routine administrative mechanism, not a substantive ruling. It confirms the court has identified common questions of law or fact across parallel ANDA challenges to CAPLYTA®. No finding on infringement, validity, or enforceability of the three lumateperone patents has been made. All merits issues will be resolved in the lead action No. 3:24-cv-04264.
US12128043B2, US12122792B2 & US12090155B2 — lumateperone capsule formulations
The three asserted patents — US12128043B2, US12122792B2, and US12090155B2 — cover formulations and potentially methods of use for lumateperone, the active ingredient in CAPLYTA®, an atypical antipsychotic approved for schizophrenia, bipolar depression, and major depressive disorder. All three patents carry recent issue dates, consistent with continuation or divisional prosecution strategies designed to maintain patent coverage as the product matures commercially. Their application numbers (18/602981, 18/240951, 18/494754) suggest they stem from a broader patent family covering lumateperone chemistry and pharmaceutical development.
Lumateperone operates via a novel multi-modal mechanism targeting serotonin, dopamine, and glutamate pathways, differentiating CAPLYTA® in a competitive CNS market. Intra-cellular Therapies’ layered patent estate — including these three recently issued patents — is designed to extend effective market exclusivity beyond earlier composition-of-matter protection. For generic manufacturers, successfully challenging all three patents in district court or via IPR is a prerequisite to obtaining FDA approval. The outcome of this consolidated proceeding will shape the competitive dynamics of the lumateperone market for years.
Should your team run an FTO against the CAPLYTA® lumateperone patent family?
Any pharmaceutical company developing a generic or biosimilar lumateperone product, or working on CNS compounds with overlapping mechanism-of-action profiles, should conduct a freedom-to-operate analysis against US12128043B2, US12122792B2, and US12090155B2. With active ANDA litigation ongoing in New Jersey and the risk of additional continuation patents issuing from the same families, the clearance landscape is dynamic. R&D teams working on atypical antipsychotic formulations should also monitor the broader Intra-cellular Therapies patent portfolio for related applications.
PatSnap Eureka’s FTO Search Agent can map the full lumateperone patent family, identify related continuations and divisionals still in prosecution, and flag claims most likely to be asserted against a proposed generic formulation. Eureka’s claim-level analysis tools allow IP teams to identify design-around opportunities and assess IPR petition viability against each of the three asserted patents — providing actionable intelligence ahead of ANDA filing or product launch decisions.
Run a freedom-to-operate analysis on US12128043B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA lumateperone and CNS pharmaceutical patent cases
Explore related Hatch-Waxman ANDA patent cases in the New Jersey District Court involving CNS pharmaceutical formulations and atypical antipsychotic compounds.
What this consolidation signals for the CAPLYTA® IP landscape
Multiple generic ANDA filers and three recently issued patents create a high-stakes, multi-front litigation environment for lumateperone.
Three recent patents extend CAPLYTA® protection — expect prolonged litigation
All three asserted patents (US12128043B2, US12122792B2, US12090155B2) were issued recently, suggesting Intra-cellular Therapies has been actively building its patent estate around lumateperone. Late-lifecycle patent filings are common in ANDA disputes and are designed to extend market exclusivity. Any company tracking CNS pharmaceutical IP should monitor prosecution history and potential IPR filings against these three patents.
New Jersey District Court consolidation signals coordinated Hatch-Waxman defence
The District of New Jersey is a primary venue for Hatch-Waxman ANDA litigation and has well-established procedures for managing consolidated pharmaceutical patent cases. Early consolidation within 70 days is standard practice. IP teams at branded and generic pharma companies should monitor the lead docket for the claim construction order, which will be the first substantive ruling likely to affect all parties.
Intra-cellular v Sandoz — key questions answered
Case No. 3:24-cv-10239 was a patent infringement action filed by Intra-cellular Therapies against Sandoz over three patents covering CAPLYTA® lumateperone capsules. The case was closed after 70 days when it was consolidated into lead action No. 3:24-cv-04264 in the District of New Jersey. No merits ruling was issued; all patent claims continue in the consolidated proceeding.
Intra-cellular Therapies asserted three patents: US12128043B2 (App. No. 18/602981), US12122792B2 (App. No. 18/240951), and US12090155B2 (App. No. 18/494754). All three cover lumateperone formulations relevant to CAPLYTA® capsules in 10.5 mg, 21 mg, and 42 mg strengths.
Consolidation under Fed. R. Civ. P. 42(a) merges this case with other parallel ANDA challenges against CAPLYTA® into lead action No. 3:24-cv-04264. It is a procedural step, not a merits ruling. All infringement and validity issues for the three lumateperone patents continue in the consolidated docket, and the 30-month Hatch-Waxman stay continues to run.
The consolidation of multiple ANDA cases suggests more than one generic manufacturer has filed Paragraph IV certifications against CAPLYTA®. However, no court has ruled on the validity or infringement of the three asserted patents. Generic entry cannot occur while the 30-month stay is in effect or until a final court ruling favouring the generic challengers. The outcome of the lead consolidated action will be determinative.
The consolidated ANDA litigation against CAPLYTA® is being handled by the U.S. District Court for the District of New Jersey under lead docket Civil Action No. 3:24-cv-04264. New Jersey is the primary venue for Hatch-Waxman pharmaceutical patent litigation in the United States due to the concentration of pharmaceutical companies in the region.
PatSnap Eureka searches patents and litigation data to answer instantly.